candesartan has been researched along with Renal Insufficiency in 10 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and five patients eligible for coronary artery bypass graft surgery (65-85 years old, all suffering from hypertension and coronary artery disease, with stable kidney function) were randomized to candesartan (8 mg od) or placebo for between 8 and 11 days prior to surgery." | 5.14 | ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting. ( Erdmann, E; Flesch, M; Geissler, HJ; Kessler, G; Knipp, S; Massoudy, P; Philipp, T; Wilhelm, H, 2009) |
| "The aim of this study was to assess the effects of angiotensin receptor blocker (ARB)-based therapy on cardiovascular events in high-risk hypertensive patients with coronary artery disease (CAD) and impaired renal function in post hoc analysis of HIJ-CREATE (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease)." | 5.14 | Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function. ( Hagiwara, N; Haze, K; Honda, T; Kasanuki, H; Kawana, M; Ogawa, H; Origasa, H; Shiga, T; Sumiyoshi, T; Takagi, A, 2010) |
| "Japanese patients with renal insufficiency were randomly assigned to receive either an ACE inhibitor (benazepril 1." | 5.12 | A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. ( Kanno, Y; Shoda, J; Suzuki, H, 2006) |
| " Candesartan significantly reduced aortic atherosclerosis, prevented the upregulation of the uraemia-induced genes and led to changes predicting greater stability of the plaques, without influencing blood pressure or serum lipids." | 3.77 | Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure. ( Bernardi, S; Candido, R; Carretta, R; Fabris, B; Toffoli, B, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, F | 1 |
| Goto, M | 1 |
| Wada, Y | 1 |
| Hasebe, N | 1 |
| Damman, K | 1 |
| Solomon, SD | 1 |
| Pfeffer, MA | 1 |
| Swedberg, K | 1 |
| Yusuf, S | 1 |
| Young, JB | 1 |
| Rouleau, JL | 1 |
| Granger, CB | 1 |
| McMurray, JJ | 1 |
| Flesch, M | 1 |
| Knipp, S | 1 |
| Kessler, G | 1 |
| Geissler, HJ | 1 |
| Massoudy, P | 1 |
| Wilhelm, H | 1 |
| Philipp, T | 1 |
| Erdmann, E | 1 |
| González Peña, O | 1 |
| Montenegro Martínez, J | 1 |
| de Los Mozos Villar, J | 1 |
| García Erauzkin, G | 1 |
| García Uriarte, O | 1 |
| Arrieta Lezama, J | 1 |
| Susic, D | 1 |
| Zhou, X | 1 |
| Frohlich, ED | 1 |
| Munk, PS | 1 |
| von Brandis, P | 1 |
| Larsen, AI | 1 |
| Shiga, T | 1 |
| Kasanuki, H | 1 |
| Hagiwara, N | 1 |
| Sumiyoshi, T | 1 |
| Honda, T | 1 |
| Haze, K | 1 |
| Takagi, A | 1 |
| Kawana, M | 1 |
| Origasa, H | 1 |
| Ogawa, H | 1 |
| Bernardi, S | 1 |
| Candido, R | 1 |
| Toffoli, B | 1 |
| Carretta, R | 1 |
| Fabris, B | 1 |
| Hünseler, C | 1 |
| Paneitz, A | 1 |
| Friedrich, D | 1 |
| Lindner, U | 1 |
| Oberthuer, A | 1 |
| Körber, F | 1 |
| Schmitt, K | 1 |
| Welzing, L | 1 |
| Müller, A | 1 |
| Herkenrath, P | 1 |
| Hoppe, B | 1 |
| Gortner, L | 1 |
| Roth, B | 1 |
| Kattner, E | 1 |
| Schaible, T | 1 |
| Shoda, J | 1 |
| Kanno, Y | 1 |
| Suzuki, H | 1 |
3 trials available for candesartan and Renal Insufficiency
| Article | Year |
|---|---|
ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2009 |
Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2010 |
A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Ben | 2006 |
7 other studies available for candesartan and Renal Insufficiency
| Article | Year |
|---|---|
Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cal | 2015 |
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Creatinine; Disease Prog | 2016 |
[Preservation of residual renal function in peritoneal dialysis by angiotensin receptor blockade].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Humans; Kidney; | 2008 |
Angiotensin blockade prevents salt-induced injury of the renal circulation in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Body We | 2009 |
Reversible fetal renal failure after maternal treatment with Candesartan: a case report.
Topics: Adult; Amniotic Fluid; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Creatinine; Fema | 2010 |
Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Benzimi | 2011 |
Angiotensin II receptor blocker induced fetopathy: 7 cases.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2011 |